Alnylam Pharmaceuticals is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics, listed on Nasdaq under the ticker ALNY and headquartered in Cambridge, Massachusetts, where it was founded in 2002 [1]. The company describes its work as discovering and developing RNAi-based medicines for genetically defined diseases [1].
Logo Index preserves an archived mark associated with Alnylam Pharmaceuticals for reference. No designer, agency, or date documentation for the identity is available in the cited sources, and specific details of the mark’s design history are not documented here.
Logo Index is an independent educational archive covering logos, visual identities and graphic design history. All trademarks and brand assets remain the property of their respective owners.
